Adrenal function in hospitalised patients with pulmonary tuberculosis treated with rifampicin

Willem Daniel Francois Venter

A research report submitted to the Faculty of Health Sciences, University of Witwatersrand, in partial fulfillment of the requirements for the degree of Master of Medicine in the branch of Internal Medicine

Johannesburg 2008
Declaration

I, Willem Daniel Francois Venter, declare that this research report is my own work. It is being submitted for the degree of Master of Medicine in the clinical discipline of Internal Medicine in the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at this or any other University.

Signature: ______________

_________day of ___________. 2008.
Dedication

Dedicated to all my medical teachers who have taken time and patience to educate me about our discipline.
Publication and presentations arising from this study

Venter WDF, Panz VR, Feldman C, Joffe BI, Adrenocortical function in hospitalised patients with pulmonary tuberculosis receiving a rifampicin-based regimen – a pilot study. South African Medical Journal 2006; 96; (1); 62-67

Venter WDF, Panz VR, Feldman C, Joffe BI, Adrenocortical function in hospitalised patients with pulmonary tuberculosis receiving a rifampicin-based regimen. Poster presentation, Society of Endocrinology, Metabolism and Diabetes of South Africa, Johannesburg, 9-12 April, 2005

Abstract from the conference published in Journal of Endocrinology, Metabolism and Diabetes of South Africa 2005; 10 (1), 37
Abstract

Introduction: Tuberculosis carries a high mortality in the days immediately after treatment. It is also the commonest cause of adrenal insufficiency in the developing world. Rifampicin is a potent hepatic enzyme inducer, and may contribute to adrenal insufficiency by accelerating cortisol breakdown. The aim of the study was to determine whether rifampicin induced accelerated catabolism of corticosteroids.

Methods: A prospective, randomised study comparing adrenal function in 20 patients with pulmonary tuberculosis in the first five days treated with two different antituberculosis regimens, one containing rifampicin, and the other ciprofloxacin.

Results: Demographic, clinical and laboratory results were similar in both groups. Both groups showed a statistically significant and similar decrease in morning cortisol, with similar responses to ACTH stimulation at both 30 and 60 minutes before and after four days of treatment. In the entire cohort, 40% demonstrated an incremental cortisol rise of <250nmol/l after ACTH stimulation on day 1. Mean basal cortisol concentrations were substantially elevated and DHEA-S levels were consistently subnormal, resulting in a high cortisol:DHEA-S ratio. No patient demonstrated overt adrenal insufficiency. There were no significant differences between the two groups before or during therapy for any electrolytes, hormones or calculated serum osmolality.

Conclusions: Rifampicin did not additionally impair adrenocortical function during the initial period of therapy.
Acknowledgements

I would like to acknowledge and thank my uncomplaining supervisors, Professor Barry Joffe and Professor Charles Feldman, and Dr Vanessa Panz, Professor Derek Raal and Professor Hendrik Koornof, for their constant support and advice, without which I would not have completed this research report. Dr Panz also helped in the preparation, coordination and submission of the publication with an extraordinary degree of perseverance and patience, and I am grateful to her for her gentle words of encouragement. I would like to thank Bayer for donating the ciprofloxacin, and to Ms van den Bergh from the Johannesburg Hospital pharmacy, for arranging the provision of the antituberculous drugs. I would also like to thank the Reproductive Health and HIV Research Unit (under Professor Helen Rees) and the Clinical HIV Research Unit (under Dr Ian Sanne), for the significant amount of time they allowed to me to pursue this project. The Department of Medicine at the University contributed R5000 through a research award to the funding of the study. Finally, I would like to thank the Bruns family and Laura Maxwell-Stewart for giving me their Cape Town homes to write all this up.
Table of contents

Page | Page number
--- | ---
Title page | i
Declaration | ii
Dedication | iii
Publications and presentations arising | iv
Abstract | v
Acknowledgements | vi
Table of contents | vii
List of figures | x
List of tables | xi

1 Introduction

1.1. Overview | 1

1.2. Tuberculosis in Southern Africa | 1

1.3. TB and mortality in the developing world | 2

1.4. Adrenal failure | 3

1.4.1. The hypothalamic-pituitary-adrenal (HPA) axis | 3

1.4.2. Causes of hypoadrenalism | 6

1.4.3. Laboratory evaluation of adrenal function | 8

1.5. TB, rifampicin and HPA axis | 10

1.5.1. Overview | 10
1.5.2. TB and adrenal function 10
1.5.3. Effects of rifampicin on steroid metabolism 14
1.5.4. Clinical cases of hypoadrenalism secondary to rifampicin 15
1.6. Role of rifampicin in treating TB 16
1.7. Rifampicin and the cytochrome systems 17
1.8. Impact and use of quinolones in treating TB 19
1.9. Summary of literature reviews 19
1.10 Background to this study 20
1.11 Aim of this study 20

2 Materials and Methods 21

2.1 Summary: 21
   2.1.1 Study population 21
   2.1.2 Informed consent 21
   2.1.3 Randomisation 22
   2.1.4 Baseline data collection 22
   2.1.5 Treatment initiation 23
   2.1.6 Biochemical and hormone assays 26
2.2 Interpretation of results 26
2.3 Statistical analysis 27
3 Results

3.1 Baseline results of participants

3.1.1 Clinical characteristics

3.1.2 Baseline laboratory data

3.1.3 Non-hormonal laboratory values on treatment

3.1.5 Hormonal laboratory values on treatment

3.1.5 Responses to cosyntropin stimulation testing

4 Discussion

5 Conclusion

6 Appendices:

1) South African Medical Journal article

2) Conference Poster

3) Human Research Ethics Committee approval form

7 References
List of figures

Figure 1: The HPA axis 5
Figure 2: Recruitment procedure 24
Figure 3: Cortisol responses during stimulation testing 40
List of tables

Table 2: Study procedure post consent 25
Table 3.1: Baseline results: Demographic and clinical 29
Table 3.2: Baseline results: Laboratory 31-34
Table 3.3: Electrolytes and renal function at baseline, day 1, 3 and 5 36
Table 3.4: Serum concentrations of pituitary and adrenal hormones in the two groups of patients during treatment. 38
Table 3.5: Cortisol concentrations during stimulation testing 40
Table 3.6: Rifampicin group: cortisol levels 41
Table 3.7: Ciprofloxacin group: cortisol levels 42